Demonstration of heterodimeric fibrinogen molecules partially conjugated with albumin in a novel dysfibrinogen: Fibrinogen Mannheim V

Summary

A 30-year-old female experienced three miscarriages in early pregnancy. Extensive laboratory screening showed a low plasma fibrinogen level of approximately 1 g/l detected by PT-derived fibrinogen assay.The fibrinogen level in the immunological assay was 3 g/l.The functional Clauss assay yielded an intermediate result of 1.78 g/l. During her fourth and fifth pregnancy, the patient received fibrinogen concentrates (Haemocomplettan, CLS Behring, Marburg, Germany), starting with 4 grams of human fibrinogen, followed by 2 grams every second day until the 15th week of pregnancy.The further course of these pregnancies was uneventful. SDS-PAGE and immunoblotting showed doublet bands in the positions of the high-molecular weight (HMW)-and lowmolecular-weight (LMW)-fibrinogen, a single LMW’ fibrinogen band, plus additional bands with higher molecular weight than HMW-fibrinogen, which were also reactive with anti-human serum albumin (HSA) antiserum. These bands correspond to variant fibrinogen conjugated with albumin. Reduced SDS-PAGE and immunoblotting using polyclonal anti-fibrinopeptide A antiserum disclosed one additional Aα-chain band with lower molecular weight. Amplification and sequencing of exon 5 of the α gene indicated heterozygosity for a novel single nucleotide deletion at codon Aα494 (C1537delA). His494 is replaced by Pro and this is followed by 23 (LMKLPSSTLPQLEKHSQ VSSHLC) new amino acids before premature truncation after Cys517, yielding a free C-terminal cysteine, which may link with albumin.This new fibrinogen mutation, leads to a balanced array of homo- and heterodimeric fibrinogen molecules, some of which are conjugated to albumin.

Keywords

Fibrinogen - dysfibrinogenemia - pregnancy complications - recurrent abortions

• References

• 1 Mosesson MW, Siebenlist KR, Meh DA. The structure and biological features of fibrinogen and fibrin. Ann NY Acad Sci 2001; 936: 11-30.
• 2 Madrazo J, Brown JH, Litvinovich S. et al. Crystal structure of the central region of bovine fibrinogen (E5 fragment) at 1.4-A resolution. Proc Natl Acad Sci USA 2001; 98: 11967-11972.
• 3 Holm B, Nilsen DW, Kierulf P. et al. Purification and characterization of 3 fibrinogens with different molecular weights obtained from normal human plasma. Thromb Res 1985; 37: 165-176.
• 4 Dempfle CE, Pfitzner SA, Schott D. et al. Fibrinogen heterogeneity in homozygous plasminogen deficiency type I: further evidence that plasmin is not involved in formation of LMW and LMW’-fibrinogen. Thromb Haemost 1997; 77: 879-883.
• 5 Olexa SA, Budzynski AZ. Evidence for four different polymerization sites involved in human fibrin formation. Proc Natl Acad Sci USA 1980; 77: 1374-1378.
• 6 Budzynski AZ, Olexa SA, Pandya BV. Fibrin polymerization sites in fibrinogen and fibrin fragments. Ann NY Acad Sci 1983; 408: 301-314.
• 7 Litvinov RI, Gorkun OV, Galanakis DK. et al. Polymerization of fibrin: Direct observation and quantification of individual B:b knob-hole interactions. Blood 2007; 109: 130-138.
• 8 Greenberg CS, Achyuthan KE, Rajagopalan S. et al. Characterization of the fibrin polymer structure that accelerates thrombin cleavage of plasma factor XIII. Arch Biochem Biophys 1988; 262: 142-148.
• 9 Mosesson MW. Fibrinogen structure and fibrin clot assembly. Semin Thromb Hemost 1998; 24: 169-174.
• 10 Matsuda M. Structure and function of fibrinogen inferred from hereditary dysfibrinogens. Int J Hematol 2000; 72: 436-447.
• 11 Siebenlist KR, Prchal JT, Mosesson MW. Fibrinogen Birmingham: a heterozygous dysfibrinogenemia (A alpha 16 Arg----His) containing heterodimeric molecules. Blood 1988; 71: 613-618.
• 12 Galanakis DK, Henschen A, Peerschke EI. et al. Fibrinogen Stony Brook, a heterozygous A alpha 16Arg----Cys dysfibrinogenemia. Evaluation of diminished platelet aggregation support and of enhanced inhibition of fibrin assembly. J Clin Invest 1989; 84: 295-304.
• 13 Okumura N, Terasawa F, Fujita K. et al. Evidence that heterodimers exist in the fibrinogen Matsumoto II (gamma308N-->K) proband and participate in fibrin fiber formation. Thromb Res 2002; 107: 157-162.
• 14 Homer VM, Mullin JL, Brennan SO. et al. Novel Aalpha chain truncation (fibrinogen Perth) resulting in low expression and impaired fibrinogen polymerization. J Thromb Haemost 2003; 01: 1245-1250.
• 15 Koopman J, Haverkate F, Grimbergen J. et al. Fibrinogen Marburg: a homozygous case of dysfibrinogenemia, lacking amino acids A alpha 461-610 (Lys 461 AAA-->stop TAA). Blood 1992; 80: 1972-1979.
• 16 Collen A, Maas A, Kooistra T. et al. Aberrant fibrin formation and cross-linking of fibrinogen Nieuwegein, a variant with a shortened Aalpha-chain, alters endothelial capillary tube formation. Blood 2001; 97: 973-980.
• 17 Margaglione M, Vecchione G, Santacroce R. et al. A frameshift mutation in the human fibrinogen Aalphachain gene (Aalpha(499)Ala frameshift stop) leading to dysfibrinogen San Giovanni Rotondo. Thromb Haemost 2001; 86: 1483-1488.
• 18 Marchi R, Carvajal Z, Meyer M. et al. Fibrinogen Guarenas, an abnormal fibrinogen with an Aalphachain truncation due to a nonsense mutation at Aalpha 467 Glu (GAA)-->stop (TAA). Thromb Res 2006; 118: 637-650.
• 19 Ridgway HJ, Brennan SO, Gibbons S. et al. Fibrinogen Lincoln: a new truncated alpha chain variant with delayed clotting. Br J Haematol 1996; 93: 177-184.
• 20 Marchi R, Meyer M, de Bosch N. et al. Biophysical characterization of fibrinogen Caracas I with an Aalpha-chain truncation at Aalpha-466 Ser: identification of the mutation and biophysical characterization of properties of clots from plasma and purified fibrinogen. Blood Coagul Fibrinolysis 2004; 15: 285-293.
• 21 Soria J, Soria C, Caen P. A new type of congenital dysfibrinogenaemia with defective fibrin lysis--Dusard syndrome: possible relation to thrombosis. Br J Haematol 1983; 53: 575-586.
• 22 Siebenlist KR, Mosesson MW, DiOrio JP. et al. The polymerization of fibrinogen Dusart (A alpha 554 Arg-->Cys) after removal of carboxy terminal regions of the A alpha-chains. Blood Coagul Fibrinolysis 1993; 04: 61-65.
• 23 Koopman J, Haverkate F, Grimbergen J. et al. Molecular basis for fibrinogen Dusart (A alpha 554 Arg-->Cys) and its association with abnormal fibrin poly- merization and thrombophilia. J Clin Invest 1993; 91: 1637-1643.
• 24 Collet JP, Woodhead JL, Soria J. et al. Fibrinogen Dusart: electron microscopy of molecules, fibers and clots, and viscoelastic properties of clots. Biophys J 1996; 70: 500-510.
• 25 Mosesson MW, Siebenlist KR, Hainfeld J. et al. The relationship between the fibrinogen D domain self-association/cross-linking site (gammaXL) and the fibrinogen Dusart abnormality (Aalpha R554C-albumin): clues to thrombophilia in the „Dusart syndrome”. J Clin Invest 1996; 97: 2342-2350.
• 26 Lijnen HR, Soria J, Soria C. et al. Dysfibrinogenemia (fibrinogen Dusard) associated with impaired fibrin-enhanced plasminogen activation. Thromb Haemost 1984; 51: 108-109.
• 27 Ridgway HJ, Brennan SO, Faed JM. et al. Fibrinogen Otago: a major alpha chain truncation associated with severe hypofibrinogenaemia and recurrent miscarriage. Br J Haematol 1997; 98: 632-639.
• 28 Edwards RZ, Rijhsinghani A. Dysfibrinogenemia and placental abruption. Obstet Gynecol 2000; 95: 1043.
• 29 Yamanaka Y, Takeuchi K, Sugimoto M. et al. Dysfibrinogenemia during pregnancy treated successfully with fibrinogen. Acta Obstet Gynecol Scand 2003; 82: 972-973.